Top-line safety and efficacy data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022

Affinia Therapeutics, an innovative gene therapy company, announced the appointment of Diana M. Brainard, M.D., to its board of directors.

Top-line data from ongoing clinical trial in patients with hypoparathyroidism expected mid-2022

Scorpion Therapeutics announced a collaboration with AstraZeneca to discover, develop and commercialize precision medicines against

Nine months after Affinia Therapeutics raised $110 million in a Series B, the biotech has set its eyes on the Nasdaq.

Scorpion Therapeutics, Inc., a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0

We know blood stem cell transplants are potential cures for serious diseases. The problem is, patients need cells from immune-compatible....

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners Funds to be used to continue...

Life sciences leader to advance Mediar’s novel platform for fibrosis

Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform Rome Therapeutics...

Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look. Vanqua Bio Closes $85...

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Disease

Studying inhaled NTX-1175, A First-In-Class, Charged Sodium Channel Blocker Phase 2a Study Expected to Enroll 40 Chronic Cough Patients

Gene editing analysis company SeQure Dx said on Tuesday that it has closed a $17.5 million Series A funding round

Lyndra Therapeutics Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other

Lyndra Therapeutics Completes $60.5 Million Series C Financing

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment...

Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie.

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-34

Investors back a $110M reboot effort. Source: EndPoints News Next week, Affinia Therapeutics will present four new abstracts at the...